ArticleBMC nephrology2026
Association between skeletal fractures and sleep medication in patients with chronic kidney disease.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFracture risk associated with sleep drugs is of great concern in patients with chronic kidney disease (CKD). However, the fracture risk among sleep drugs with different mechanisms of action remains controversial. This study aimed to examine how fracture risk differs between the use of benzodiazepine receptor agonists (BDZRA) and dual orexin receptor antagonists (DORA) in patients with CKD.
methodsA large-scale Japanese medical claims database of patient data collected between April 2008 and August 2021 was analysed. The association between composite hip and vertebral body fracture risk and continuous prescription of DORA or BDZRA was examined using a Cox proportional hazards model. Propensity score matching was employed to reduce confounding.
resultsDORA and BDZRA were prescribed to 4,504 and 22,080 patients, respectively. The BDZRA group showed a lower cumulative incidence rate of composite hip and vertebral body fractures than the DORA group (hazard ratio [HR]: 0.67, p = 0.06 in the unmatched cohort and HR: 0.64, p = 0.129 in the matched cohort). The risk of hip fracture alone was comparable for both the unmatched cohort (HR: 0.83, p = 0.507) and matched cohort (HR: 0.94, p = 0.869). The risk of vertebral body fracture alone was significantly lower in both the unmatched and matched cohorts (HR: 0.45, p = 0.021 for the unmatched cohort and HR: 0.23, p = 0.023 for the matched cohort).
conclusionsThe results suggest a possible association between DORA prescription and bone metabolism in patients with CKD. DORA should be used with caution in these patients. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.